NEW YORK (GenomeWeb) – Biotech firm X-Chem today announced a multi-target collaboration with Pfizer for the potential development of new treatments for inflammatory and orphan diseases.

X-Chem will apply its discovery engine to identify new leads for several of Pfizer's treatment development programs. Pfizer has an exclusive option to license compounds generated from the collaboration. Further details of the deal were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.